 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C27H42O4 |
| Molar mass | 430.629 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
AM-4030 is ananalgesic drug which is acannabinoid receptor agonist. It is a derivative ofHU-210 which has been substituted with a 6β-((E)-3-hydroxyprop-1-enyl) group. This adds a "southern"aliphatichydroxyl group to the molecule as seen in theCP-series of nonclassicalcannabinoid drugs, and so AM-4030 represents a hybrid structure between the classical and nonclassical cannabinoid families,[1] with the 6-hydroxyalkyl chain rigidified with adouble bond with definedstereochemistry. This gives AM-4030 a greater degree of selectivity, so while it is still a potent agonist at bothCB1 andCB2, it is reasonably selective for CB1, with aKi of 0.7nM at CB1 and 8.6nM at CB2, a selectivity of around 12x.[2][3] Resolution of the enantiomers of AM-4030 yields an even more potent compound, although with less selectivity, with the (−) enantiomerAM-4030a having a Ki of 0.6nM at CB1 and 1.1nM at CB2.[4]
